West Pharmaceutical Services Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.9%projected annual EPS growth
Analyst Coverage
15analysts covering
FY Revenue (est.)
$3.4Bnext fiscal year
FY EPS (est.)
$8.96next fiscal year
Monitoring Framework
Key Performance Indicators
High-Value Product (HVP) Components Organic Growth Quarterly2,300.0%Target: Double-digit growth
GLP-1 Elastomer Revenue Contribution Quarterly10.0Target: Sustained expansion to support long-term growth
Biologics and Biosimilars Win Rate Quarterly9,000.0%Target: >90%
Watch Items
- SmartDose 3.5ml Divestiture to AbbVieTrigger: Mid-year 2026 closeAction: Monitor for a $40 million revenue headwind in the second half of 2026 and evaluate replacement growth timing.
- CEO Transition to Michel LagardeTrigger: August 31, 2026Action: Track operational execution, integration of the new CEO, and potential shifts in capital allocation or restructuring strategies.
- Annex 1 Regulatory ConversionsTrigger: 700 active customer projectsAction: Assess the conversion rate of active projects into commercialized, high-margin HVP revenue.
Research as of 2 Sep 2026